Phase II trial with tamoxifen in combination with vorinostat and pembrolizumab in estrogen receptor (+) hormone therapy resistant metastatic breast cancer patients (NCT02395627) von Terranova Barberio, Manuela, Thomas, Scott, Chien, Amy Jo, Rugo, Hope S., Melisko, Michelle E., Angelidakis, Austin Nicholas, Pawlowska, Nela, Deal, Travis, Munster, Pamela N.

Volltext

Long term follow up (LTFU) of adjuvant zoledronic acid (ZOL) in high risk early stage breast cancer (ESBC) defined by bone marrow (BM) disseminated tumor cells (DTC) von Vidula, Neelima, Hwang, Jimmy, Greenberg, Sally, Melisko, Michelle E., Goga, Andrei, Moasser, Mark, Cudos, Ariadna Gasol, Angelidakis, Austin Nicholas, DeLuca, Amy, Petrillo, Laura A, Magbanua, Mark Jesus Mendoza, Park, John, Rugo, Hope S.

Volltext

Addition of pazopanib (PZ) to endocrine therapy in hormone resistant advanced breast cancer (ABC) von Majure, Melanie Catherine, Gasol Cudós, Ariadna, Angelidakis, Austin Nicholas, Melisko, Michelle E., Karwat, Ariel R., Chien, Amy Jo, Goga, Andrei, Moasser, Mark M., Park, John W., DeLuca, Amy N., Rugo, Hope S.

Volltext